Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Sells $163,398.90 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $17.85, for a total transaction of $163,398.90. Following the completion of the sale, the chief executive officer now directly owns 642,602 shares of the company’s stock, valued at approximately $11,470,445.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jeremy Bender also recently made the following trade(s):

• On Wednesday, May 1st, Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $15.25, for a total value of $116,128.75.

Day One Biopharmaceuticals Trading Down 2.3 %

Shares of DAWN opened at $17.17 on Monday. The company’s fifty day simple moving average is $15.45 and its 200-day simple moving average is $14.07. The company has a market cap of $1.50 billion, a P/E ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DAWN has been the topic of a number of research reports. Needham & Company LLC raised their price objective on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. The Goldman Sachs Group reduced their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. China Universal Asset Management Co. Ltd. boosted its position in Day One Biopharmaceuticals by 67.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after buying an additional 6,750 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock worth $999,000 after purchasing an additional 32,238 shares during the period. Wellington Management Group LLP boosted its stake in shares of Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after purchasing an additional 91,393 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after buying an additional 472,654 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.